ID: ALA3122123

Max Phase: Preclinical

Molecular Formula: C92H131N21O24S2

Molecular Weight: 1979.32

Molecule Type: Protein

Representations

Canonical SMILES:  CCCC[C@H](NC(=O)CNC(=O)[C@H](C)NC(=O)CN1CCN(CC(=O)O)CCN(CC(=O)O)CCN(CC(=O)O)CC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@H]1CSSC[C@@H](C(=O)N[C@@H](CO)C(=O)NCC(=O)O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](Cc2c[nH]c3ccccc23)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2ccccc2)NC1=O

Standard InChI:  InChI=1S/C92H131N21O24S2/c1-4-5-28-64(99-74(116)47-96-81(126)56(2)98-75(117)49-110-34-36-111(50-77(120)121)38-40-113(52-79(124)125)41-39-112(37-35-110)51-78(122)123)83(128)100-65(30-17-19-32-93)84(129)107-72-54-138-139-55-73(91(136)106-71(53-114)82(127)97-48-76(118)119)108-88(133)69(44-60-25-13-8-14-26-60)105-92(137)80(57(3)115)109-85(130)66(31-18-20-33-94)101-89(134)70(45-61-46-95-63-29-16-15-27-62(61)63)104-87(132)67(42-58-21-9-6-10-22-58)102-86(131)68(103-90(72)135)43-59-23-11-7-12-24-59/h6-16,21-27,29,46,56-57,64-73,80,95,114-115H,4-5,17-20,28,30-45,47-55,93-94H2,1-3H3,(H,96,126)(H,97,127)(H,98,117)(H,99,116)(H,100,128)(H,101,134)(H,102,131)(H,103,135)(H,104,132)(H,105,137)(H,106,136)(H,107,129)(H,108,133)(H,109,130)(H,118,119)(H,120,121)(H,122,123)(H,124,125)/t56-,57+,64-,65-,66-,67-,68-,69-,70+,71-,72-,73-,80-/m0/s1

Standard InChI Key:  UXKXLWHPLWJRQG-DHHLODHWSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Protein

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 1979.32

Molecular Weight (Monoisotopic): 1977.9117

AlogP:

#Rotatable Bonds:

Polar Surface Area:

Molecular Species:

HBA:

HBD:

#RO5 Violations:

HBA (Lipinski):

HBD (Lipinski):

#RO5 Violations (Lipinski):

CX Acidic pKa:

CX Basic pKa:

CX LogP:

CX LogD:

Aromatic Rings:

Heavy Atoms:

QED Weighted:

Np Likeness Score:

References

1. Tatsi A, Maina T, Cescato R, Waser B, Krenning EP, de Jong M, Cordopatis P, Reubi JC, Nock BA..  (2014)  [DOTA]Somatostatin-14 analogs and their (111)In-radioligands: effects of decreasing ring-size on sst1-5 profile, stability and tumor targeting.,  73  [PMID:24378707] [10.1016/j.ejmech.2013.12.003]

Source

Source(1):

• Scientific Literature